Shares of Unum Therapeutics Inc (NASDAQ:UMRX) have been given a consensus recommendation of “Buy” by the six brokerages that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $13.80.
A number of research firms have recently weighed in on UMRX. Zacks Investment Research cut Heritage Insurance from a “hold” rating to a “strong sell” rating in a report on Friday, April 26th. SunTrust Banks reiterated a “hold” rating and set a $25.00 price target on shares of Simply Good Foods in a report on Wednesday, July 3rd. Finally, HC Wainwright set a $51.00 price target on Amarin and gave the stock a “buy” rating in a report on Wednesday, July 3rd.
Institutional investors have recently made changes to their positions in the stock. American International Group Inc. boosted its holdings in Unum Therapeutics by 432.8% during the 4th quarter. American International Group Inc. now owns 12,531 shares of the company’s stock valued at $55,000 after acquiring an additional 10,179 shares during the period. Rhumbline Advisers purchased a new position in Unum Therapeutics during the 1st quarter valued at about $85,000. Bank of New York Mellon Corp boosted its holdings in Unum Therapeutics by 251.5% during the 4th quarter. Bank of New York Mellon Corp now owns 46,248 shares of the company’s stock valued at $204,000 after acquiring an additional 33,091 shares during the period. D. E. Shaw & Co. Inc. boosted its holdings in Unum Therapeutics by 7.5% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 54,956 shares of the company’s stock valued at $242,000 after acquiring an additional 3,846 shares during the period. Finally, Deutsche Bank AG boosted its holdings in Unum Therapeutics by 72.4% during the 4th quarter. Deutsche Bank AG now owns 63,657 shares of the company’s stock valued at $279,000 after acquiring an additional 26,742 shares during the period. Institutional investors own 47.27% of the company’s stock.
Unum Therapeutics (NASDAQ:UMRX) last released its quarterly earnings results on Monday, May 13th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.08). The business had revenue of $3.05 million for the quarter, compared to analysts’ expectations of $3.15 million. Unum Therapeutics had a negative return on equity of 62.24% and a negative net margin of 373.81%. On average, sell-side analysts forecast that Unum Therapeutics will post -1.32 EPS for the current year.
About Unum Therapeutics
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).
See Also: What is dividend yield?
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.